VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-1 1 with a maximal effect observed at 0.5mg to 1.0 mg QD. For more information on the Phase 1a trial results, please ...

With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / ...